Sydney Hiller, PhD

More about Sydney

Sydney’s ability to distill intricate scientific concepts into clear, actionable regulatory and product development strategies has consistently driven success in high-stakes, highly regulated environments. Her work spans early-stage innovation through post-market compliance, encompassing extensive experience in aligning scientific evidence with evolving global regulatory expectations. 

​

In addition to her graduate research on cannabinoids and the CB2 receptor, Sydney worked under the late Professor Raphael Mechoulam—widely recognized as the father of cannabis research—gaining rare, firsthand insight into the foundational chemistry and pharmacology that underpin today’s cannabinoid-based therapeutics. This experience gives her a distinct advantage in advising cannabis businesses, enabling her to bridge deep scientific understanding with regulatory strategy, product development, and commercialization planning. Her background is particularly valuable to companies navigating evolving global frameworks for cannabinoid-based products, where credibility, technical accuracy, and strategic foresight are critical to success. 

Sydney's graduate work under Professor Fokin, one of the preeminent thought leaders who redefined and reshaped the concept of click chemistry, focused on practical applications of this powerful synthetic methodology. It is now widely employed in the creation of life-saving therapeutics, where heterocyclic moieties are integral for molecular design and function. Her deep understanding of click chemistry equips her with unique insight into modern drug design, lead optimization, and CMC strategy. This background gives her a strategic edge in supporting pharmaceutical clients through early-stage development, regulatory submissions, and technical problem-solving. 

​